ArticleFrontiers in oncology2022

Could We Safely Avoid a Second Resection in Selected Patients With T1 Non-Muscle-Invasive Bladder Cancer? Preliminary Results of Cost-Effectiveness Study From HUmanitas New Indications for ReTUR (HuNIRe) Multicenter Prospective Trial.

Roberto Contieri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.